CARsgen Therapeutics’ Post

Our latest study is now online at Frontiers in Oncology! In our study, we identified two robust predictors for taxane-based neoadjuvant chemotherapy in ER /HER2-breast cancer. These two predictors have a high potential for translation into the clinics both as tools that guide treatment decisions and also as drug targets. We are excited about our new projects to translate this potential! #cancerresearch #precisionmedicine #biomarkerdiscovery #breastcancer #chemoresistance #cancerchemotherapy #medicine #pharmacology #bioinformatics #datascience #GOLab #KoçUniversity #KoçUniversitySchoolofMedicine #KUSOM #KUTTAM #KoçUniversityResearchCenterforTranslationalMedicine

Great news for PIK3CA-mutated HR-positive, HER2 negative breast cancer patients. Genentech Phase III INAVO120 study meets primary objective of positive PFS of inavolisib in combination with palbociclib and fulvestrant  compared to palbociclib and fulvestrant in the 1st line. Nice to see results for Inavolisib in this setting considering its inhibition of PI3K p110a catalytic subunit in the context of HER2 negativity where attenuating feed back upon signaling mechanism is absent. https://lnkd.in/eEAnmaAw #breastcancer #clinicaloncology #oncologyphaseIII

In the NaPi2b-positive population, the experimental agent yielded an ORR of 15.6% (95% CI, 10.0%-22.7%) according to investigator assessment; this consisted of 20 partial responses (14.2%) and 2 complete responses (1.4%). https://ow.ly/kAsQ50Pwbc0 #gyncsm #cancer #oncology

🎉 Big news in cancer treatment! 🎉 The #FDA granted full approval to #Pfizer and #Genmab’s #Tivdak for recurrent or metastatic cervical cancer post-chemotherapy. It's the first #ADC with significant overall survival data. Results from Phase III innovaTV 301 trial showed a 30% reduction in the risk of death and a 33% reduction in disease progression or death compared to chemotherapy. Though effective, #Tivdak carries a boxed warning for ocular toxicity. This milestone underscores the dedication to advancing cancer care. #FDAApproval #CancerTreatment #Tivdak #Pfizer #Genmab #RASLifescienceSolutions #RASLSS Follow our page for more industry updates: https://lnkd.in/dGRWp6FD

Major breakthrough in cervical cancer treatment! 🎉 Pfizer & Genmab's TIVDAK (tisotumab vedotin-tftv) receives full FDA approval for recurrent/metastatic cervical cancer. This marks a significant advancement, offering improved survival outcomes for patients. #Pfizer #Genmab #ADCs #TIVDAK #FDAApproval #Oncology #CervicalCancer #Cancer #HealthcareInnovation

𝙀𝙛𝙛𝙞𝙘𝙖𝙘𝙮 𝙖𝙣𝙙 𝙨𝙖𝙛𝙚𝙩𝙮 𝙤𝙛 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙥𝙚𝙣𝙥𝙪𝙡𝙞𝙢𝙖𝙗 𝙖𝙨 𝙨𝙚𝙘𝙤𝙣𝙙-𝙡𝙞𝙣𝙚 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙛𝙤𝙧 𝙨𝙢𝙖𝙡𝙡 𝙘𝙚𝙡𝙡 𝙡𝙪𝙣𝙜 𝙘𝙖𝙣𝙘𝙚𝙧: 𝘼 𝙢𝙪𝙡𝙩𝙞𝙘𝙚𝙣𝙩𝙚𝙧, 𝙤𝙥𝙚𝙣-𝙡𝙖𝙗𝙚𝙡, 𝙨𝙞𝙣𝙜𝙡𝙚-𝙖𝙧𝙢 𝙥𝙝𝙖𝙨𝙚 𝙄𝙄 𝙩𝙧𝙞𝙖𝙡. A combination of #anlotinib and #penpulimab is a promising and safe #secondlinetherapy for patients with #smallcelllungcancer who face instances of first-line standard #chemotherapy failures. Read more in this #CancerPathogenesisAndTherapy article:  https://lnkd.in/ezydRnfu

T-DXd Established as Standard of Care Following ET in HER2-Low, -Ultralow HR Metastatic Breast Cancer: Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR ), HER2-low or -ultralow disease that progressed following endocrine therapy (ET). #finance #pharmacy #lifesciences

💥The following paper: "Investigational Drug Treatments for Triple-Negative Breast Cancer" is published in the Journal of Personalized Medicine MDPI at: https://lnkd.in/gUTce5aJ We invite you to read this paper at the above link. And also hope that you could consider JPM (https://lnkd.in/g3jxwN_H) when submitting your next paper. #personalizedmedicine #precisionmedicine #breastcancer

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

Today, we had the privilege of sharing the latest data from our ongoing Phase 1/2 trial of WU-CART-007 at the American Society of Hematology Annual Meeting & Exposition. #ASH23 Initial favorable results underscore our ongoing progress in advancing Wugen’s mission to leverage cutting-edge CAR-T therapies for difficult-to-treat blood cancers. Learn more about the latest data on WU-CART-007 here: https://bit.ly/3tnauB8 #clinicaltrials #immunotherapy #oncology #biotechnology